e-SPACE Cardio-Renal-Metabolic 2024
Published: 29 March 2024
-
Views:
211
-
Likes:
7
-
Views:
211
-
Likes:
7
-
Up Next -
16m 6s
-
1h 10s
-
1h 8m 49sPart 2 | Session 4 Plenary Session 8 – Early intervention and intensive management
-
27m 17sPart 2 | Session 5 Effects of GLP- 1RA on kidney outcomes in CKD and T2D
-
1h 3m 47sPart 2 | Session 6 Plenary Session 9 – Precision medicine in CRM
-
1h 6sPart 1 | Session 1 Plenary Session 1 – Multidisciplinary implementation strategies Gerasimos Filippatos, Manisha Sahay, Gianluigi Savarese, Francesco Cosentino, Sam Seidu
-
28m 56sPart 1 | Session 2 Keynote Session – KDIGO guideline updates 2024 Paul Stevens
-
1h 2m 27sPart 1 | Session 3 Plenary Session 2 – Guideline directed therapy for CRM disease: the evidence base Intissar Haddiya, Lars H Lund, Marco Metra, Nikolaus Marx, Peter Rossing, Giuseppe Rosano
-
59m 47sPart 1 | Session 4 Plenary Session 3 – Managing the patients with CRM: who gets what, when and why? Gianluigi Savarese, Alice Cheng, Adeera Levin, Antonio Ceriello, Shelley Zieroth, Giuseppe Rosano
-
57m 21sPart 1 | Session 5 Plenary Session 4 – Weight homeostasis management in CRM disease (Organised with support from Charité Friends & Sponsors Trust) Scott Isaacs, Peter Rossing, Muthiah Vaduganathan, Stefan Anker, Javed Butler
-
1h 7sPart 1 | Session 6 Plenary Session 5 – CRM disease: epidemiology and pathophysiology Ahmed Bennis, Ileana L Piña, Giulia Ferrannini, Chiadi Ndumele, Rodica Pop-Busui, Mitja Lainscak
Overview
KDIGO and Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology were delighted to announce the return of e-SPACE Cardio-Renal-Metabolic (CRM) 2024.
A thoughtfully curated programme supported the exploration of how leading experts, in cardiology, nephrology and diabetology, treat the interrelated diseases.
This event once again brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Related sessions to e-SPACE Cardio-Renal-Metabolic 2024:
Learning Objectives
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease and obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
Target Audience
- Cardiologists
- Nephrologists
- Diabetologists
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
John GF Cleland
Professor of Cardiology
Prof John Cleland is a Professor of Cardiology at University of Glasgow, Glasgow, UK.
In 1977, he qualified from the University of Glasgow, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation.
His main interests include heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines.
He founded the European Journal of Heart Failure and is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure.
Gerasimos Filippatos
Professor of Cardiology
Prof Gerasimos Filippatos is a Professor of Cardiology and Cardiologist at National and Kapodistrian University of Athens, Athens, GR.
He studied Medicine at the University of Patras, and earned his doctorate Cum Laude from the University of Athens.
Prof Filippatos is Past President of the Heart Failure Association (HFA) of the European Society of Cardiology and he has published over 600 articles in peer-reviewed journals and authored more than 30 book chapters.
Ewa Jankowska
Prof Ewa Jankowska is Professor of Medicine and Head of Laboratory of Applied Research on Cardiovascular System at the Department of Heart Diseases, Wroclaw Medical University, Poland. Her clinical and research interests include the role of peripheral mechanisms in the progression of heart failure, co-morbidities in heart failure, and experimental model of tachycardia-induced cardiomyopathy.
Prof Jankowska is an Editorial Board member of Cardiac Failure Review.
David Wheeler
David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.Professor Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, intravenous iron, sodium–glucose co-transporter 2 inhibitors and hypoxia-inducible factor stabilisers in patients with CKD.Professor Wheeler has also been involved in the development of clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-Chair between 2012 and 2019. His ongoing roles include serving as the National Specialty Lead for the National Institute of Health Research…
Kieran Docherty
Clinical Lecturer (Institute of Cardiovascular & Medical Sciences)
Kieran Docherty studied medicine at the University of Glasgow from 2005-2011. He is a Cardiology Specialist Registrar in the West of Scotland Deanery and a Clinical Research Fellow at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. He is undertaking a PhD examining the effects of neprilysin inhibition on left ventricular remodelling.
Comments